Tango Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $62.4M | $42.1M | $36.5M | $24.9M | $37.0M | $7.7M |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| Operating Expenses | ||||||
| Research & Development | $132.2M | $143.9M | $115.2M | $105.9M | $77.6M | $50.0M |
| SG&A Expense | $41.5M | $43.7M | $35.5M | $30.0M | $17.6M | $9.9M |
| Operating Income | $-111.3M | $-145.6M | $-114.2M | $-111.1M | $-58.2M | $-52.2M |
| Operating Margin | -178.4% | -346.1% | -312.6% | -446.8% | -157.1% | -681.8% |
| Interest Expense | — | — | — | — | — | — |
| Pretax Income | $-101.6M | $-130.1M | $-101.6M | $-108.1M | $-57.9M | $-52.0M |
| Income Tax Expense | $4.0K | $208.0K | $134.0K | $54.0K | $292.0K | $0 |
| Net Income | $-101.6M | $-130.3M | $-101.7M | $-108.2M | $-58.2M | $-52.0M |
| Net Margin | -162.9% | -309.7% | -278.5% | -435.1% | -157.2% | -678.8% |
| EPS (Basic) | $-0.87 | $-1.19 | $-1.08 | $-1.23 | $-0.94 | $-1.63 |
| EPS (Diluted) | $-0.87 | $-1.19 | $-1.08 | $-1.23 | $-0.94 | $-1.63 |
| Shares Outstanding (Basic) | 116.2M | 109.2M | 94.6M | 87.8M | 62.1M | 40.4M |
| Shares Outstanding (Diluted) | 116.2M | 109.2M | 94.6M | 87.8M | 62.1M | 40.4M |
| Dividends Per Share | — | — | — | — | — | — |